Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
0.9837
-0.0463 (-4.50%)
At close: Sep 15, 2026, 4:00 PM EDT
1.020
+0.036 (3.69%)
After-hours: Sep 15, 2026, 7:43 PM EDT
Actuate Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Oral elraglusib is advancing to clinical trials, aiming to improve survival in metastatic pancreatic and other cancers, with strong efficacy and synergy data supporting its use in combination regimens. Pediatric trials and regulatory strategies are underway, with the oral pivot expected to enhance patient outcomes.
Fiscal Year 2025
-
A large phase II randomized trial of elraglusib in first-line metastatic pancreatic cancer showed a significant and durable overall survival benefit, with a favorable safety profile and improved quality of life. The drug's unique mechanism and combinability position it as a promising new platform for pancreatic and other GI cancers.